AI-based solution for brain age evaluation and Alzheimer's disease prediction

在英国，痴呆症是导致死亡的主要原因。大约有85万人患有痴呆症，但其中只有54万人得到了诊断。准确的早期或及时诊断痴呆症可以带来许多好处，包括为未来的护理和治疗打开大门。痴呆症是一种深刻改变生活的疾病，对诊断的反应可以从沮丧和深深的悲伤到愤怒和绝望。早期诊断使痴呆症患者能够接受适当的治疗，这可能有助于他们更长时间地保持认知功能和生活质量。由intervision开发的专有人工智能解决方案提供准确的早期痴呆诊断和特征，并通过MRI扫描高精度地预测痴呆的症状前风险。intervision的解决方案代表了一个突破，它将提供一个自动化、可扩展和个性化的医疗保健平台，用于使用多模态成像和非成像MRI数据协助组织修饰性疾病的临床诊断；对病人的治疗都很有用，重要的是，在开发新的治疗方法。这项尖端技术可以自动智能地分析扫描结果，提供有关重要组织和器官结构的敏感而精确的微观结构信息，然后将这些信息与健康人群的数据进行比较，以识别痴呆症的迹象。据信，该公司的人工智能解决方案有可能加速临床途径，标准化护理质量，改善患者预后，节省痴呆症评估期间的时间，并有助于开发改善疾病的疗法。该解决方案旨在成为临床实践和药物开发的常规部分，因为它为临床医生，研究人员和成像中心提供可靠，定量和客观的诊断和预后数据，使用我们的智能分析结果。

Dementia is the leading cause of death in the UK. Around 850,000 individuals are living with dementia, but only around 540,000 of these have received a diagnosis. An accurate early, or timely diagnosis of dementia can have many benefits including opening the door to future care and treatment. Dementia is a profoundly life-changing condition and reactions to a diagnosis can range from dismay and deep sadness to anger and despair. Early diagnosis allows people with dementia to receive appropriate treatment that can potentially help them maintain their cognitive function and quality of life for longer.The proprietory AI solution developed by Infervision offers accurate and early stage dementia diagnosis and characterisation, and predicts the pre-symptomatic risk of developing dementia with high accuracy using MRI scans. Infervision's solution represents a breakthrough that would provide an automated, extensible, and personalised healthcare platform for assisting the clinical diagnosis of tissue modifying diseases using multi-modal imaging and non-imaging MRI data; useful for both the treatment of patients, and importantly, in the development of novel therapeutics. The cutting-edge technology can analyse scans automatically and intelligently to deliver sensitive and precise micro-structural information about important tissue and organ structures, which can then be compared to data from healthy populations to identify the signs of dementia.It is believed that this Infervision's AI solution has the potential to accelerate clinical pathways, standardise quality of care, improve patient outcomes, and save time during assessments for Dementia, as well as contribute to the development of disease-modifying therapies. The solution is intended to become a routine part of clinical practice and drug development because it provides clinicians, researchers, and imaging centres with reliable, quantitative, and objective diagnostic and prognostic data using the results of our intelligent analysis.